{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T06:59:55Z","timestamp":1792738795586,"version":"4.5.0"},"reference-count":14,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Archives of Medical Research"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.arcmed.2020.06.004","type":"journal-article","created":{"date-parts":[[2020,6,6]],"date-time":"2020-06-06T05:05:12Z","timestamp":1591419912000},"page":"741-742","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":102,"title":["Could Respiratory Fluoroquinolones, Levofloxacin and Moxifloxacin, Prove to be Beneficial as an Adjunct Treatment in COVID-19?"],"prefix":"10.1016","volume":"51","author":[{"given":"Irene","family":"Karampela","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Dalamaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.arcmed.2020.06.004_bib1","article-title":"Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis","author":"Mehra","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.arcmed.2020.06.004_bib2","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2007764","article-title":"Remdesivir for the Treatment of Covid-19 - Preliminary Report","author":"Beigel","year":"2020","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"10.1016\/j.arcmed.2020.06.004_bib3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/jac\/dkg212","article-title":"Development of the quinolones","volume":"51","author":"Andersson","year":"2003","journal-title":"J Antimicrob Chemother"},{"issue":"Suppl 2","key":"10.1016\/j.arcmed.2020.06.004_bib4","doi-asserted-by":"crossref","first-page":"6","DOI":"10.2165\/00003495-199958002-00002","article-title":"Mode of action of fluoroquinolones","volume":"58","author":"Hooper","year":"1999","journal-title":"Drugs"},{"key":"10.1016\/j.arcmed.2020.06.004_bib5","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1164\/rccm.201908-1581ST","article-title":"Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America","volume":"200","author":"Metlay","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.arcmed.2020.06.004_bib6","doi-asserted-by":"crossref","first-page":"111","DOI":"10.2174\/1568005043340920","article-title":"Antiviral properties of quinolone-based drugs","volume":"4","author":"Richter","year":"2004","journal-title":"Curr Drug Targets Infect Disord"},{"key":"10.1016\/j.arcmed.2020.06.004_bib7","doi-asserted-by":"crossref","DOI":"10.3390\/v10120678","article-title":"Identification of Diaryl-Quinoline Compounds as Entry Inhibitors of Ebola Virus","volume":"10","author":"Cui","year":"2018","journal-title":"Viruses"},{"key":"10.1016\/j.arcmed.2020.06.004_bib8","doi-asserted-by":"crossref","first-page":"467","DOI":"10.3851\/IMP1937","article-title":"Fluoroquinolones inhibit HCV by targeting its helicase","volume":"17","author":"Khan","year":"2012","journal-title":"Antivir Ther"},{"key":"10.1016\/j.arcmed.2020.06.004_bib9","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1016\/j.bbmt.2010.12.700","article-title":"Efficacy and safety of ciprofloxacin for prophylaxis of polyomavirus BK virus-associated hemorrhagic cystitis in allogeneic hematopoietic stem cell transplantation recipients","volume":"17","author":"Miller","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.arcmed.2020.06.004_bib10","author":"Marciniec"},{"key":"10.1016\/j.arcmed.2020.06.004_bib11","doi-asserted-by":"crossref","first-page":"e0130248","DOI":"10.1371\/journal.pone.0130248","article-title":"Pleiotropic Effects of Levofloxacin, Fluoroquinolone Antibiotics, against Influenza Virus-Induced Lung Injury","volume":"10","author":"Enoki","year":"2015","journal-title":"PLoS One"},{"issue":"Suppl 2","key":"10.1016\/j.arcmed.2020.06.004_bib12","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s15010-005-8209-8","article-title":"Immunomodulatory activities of fluoroquinolones","volume":"33","author":"Dalhoff","year":"2005","journal-title":"Infection"},{"key":"10.1016\/j.arcmed.2020.06.004_bib13","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1179\/joc.2003.15.6.558","article-title":"Diffusion of oral and intravenous 400 mg once-daily moxifloxacin into lung tissue at pharmacokinetic steady-state","volume":"15","author":"Breilh","year":"2003","journal-title":"J Chemother"},{"key":"10.1016\/j.arcmed.2020.06.004_bib14","doi-asserted-by":"crossref","first-page":"71","DOI":"10.2165\/11634300-000000000-00000","article-title":"Moxifloxacin safety: an analysis of 14 years of clinical data","volume":"12","author":"Tulkens","year":"2012","journal-title":"Drugs R D"}],"container-title":["Archives of Medical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0188440920309243?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0188440920309243?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T19:49:27Z","timestamp":1759261767000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0188440920309243"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":14,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["S0188440920309243"],"URL":"https:\/\/doi.org\/10.1016\/j.arcmed.2020.06.004","relation":{},"ISSN":["0188-4409"],"issn-type":[{"value":"0188-4409","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Could Respiratory Fluoroquinolones, Levofloxacin and Moxifloxacin, Prove to be Beneficial as an Adjunct Treatment in COVID-19?","name":"articletitle","label":"Article Title"},{"value":"Archives of Medical Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.arcmed.2020.06.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 IMSS. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}